Manager of B2B Marketing, Calibrate

The company's program integrates GLP-1 medications with physician-guided care and personalized coaching. These drugs have shown strong results in clinical trials, but questions remain about long-term safety an whether weight loss can be sustained after patients stop taking them. Calibrate's approach aims to address that challenge by pairing medication with lasting behavior change.

Since launching, more than 100,000 members have participated in the program, generating one of the industry's largest real-world datasets on physician-guided weight and metabolic health outcomes. In recent years, the company has shifted away from its original direct-to-consumer model and now focuses on partnerships with employers and health plans. This move reflects growing demand from organizations seeking structured solutions to manage the rising costs and long-term use of GLP-1 medications.